Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Wrist-Access stent shows promise for leg artery blockages

NCT ID NCT05372952

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a new stent (Dynetic-35) can safely open blocked arteries in the leg when inserted through the wrist instead of the groin. Twenty-five people with peripheral artery disease took part, and the main goal was to see if the procedure was safe and feasible. The study lasted 30 days and focused on complications and technical success.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

25 people

The number who actually took part.

Started

Jul 2022

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients from vascular center of the clinic.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subject is ≥ 18 years 2. Subject is capable (no legally authorized representative allowed) to provide written informed consent as approved by the Institutional Review Board (IRB)/Ethics Committee (EC) of the respective clinical site prior to any study related procedure 3. Subject has provided written informed consent before any study specific test or procedure and is willing to comply with all protocol and follow-up requirements 4. Subjects have a target lesion(s) with ≥ 70% stenosis (visual estimate) located in the iliac arteries 5. Target lesion is a de novo, restenotic or occluded lesion 6. Reference lumen (vessel) diameter between 5mm and 10 mm 7. The target lesion can be successfully crossed with a guide wire 8. Patient is eligible for transradial access 9. Subject has symptomatic iliac artery disease defined as Rutherford category 2 or higher Exclusion Criteria: 1. Subject is pregnant and/or breastfeeding or planning to become pregnant during the course of the study. 2. Subject is with a current medical condition with a life expectancy of less than one year. 3. Pre-existing target iliac artery aneurysm or perforation or dissection 4. Any medical condition that in the opinion of the investigator poses an unacceptable risk for implant of a stent according to the study indications like, sensitivity to metal ions, intolerance to contrast or antiplatelet, anticoagulant or thrombolytic medications required per the protocol 5. Abdominal aortic aneurysm (AAA) contiguous to the iliac artery target lesion requiring treatment 6. The subject is currently participating in an investigational drug, biologic, or another device study and has not reached their primary endpoint yet 7. Subjects with small diameter upper extremity arteries that posed a contraindication to the use of 6F sheath 8. Severe stenosis or calcification of upper extremity arteries 9. Patient height precluding transradial access with a 170 cm long catheter shaft 10. Patient with a history of aortic arch atheroembolism 11. Infrainguinal outflow lesions that need to be treated during the same index procedure 12. Patients with negative bilateral Allen or barbeau tests (Note: vascular access should be done via the left hand where possible) 13. Subject has IFU listed contraindication(s) 14. Subject has in-stent restenosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Peripheral arterial disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Vascular center of Klinikum Hochsauerland GmbH

    Arnsberg, 59759, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.